Loading
Oncology testing executive Vishal Sikri has been named president and chief commercial officer of Inivata, an English-based subsidiary of Fort Myers-based NeoGenomics, a cancer-focused genetic testing services and oncology contract research firm.
Sikri, who officially starts his role May 23, replaces Inivata President Dr. Clive Morris, who will assist during the leadership transition period, according to a statement.
Vishal Sikri has more than 20 years of experience in the somatic diagnostics space and most recently was president of oncology at Invitae, a San Francisco-based biotechnology company. Prior to Invitae, Vishal was U.S. general manager for Biocartis, leading all commercial operations. He has extensive precision medicine experience, the release adds, having launched and commercialized tests for therapy selection and molecular residual disease in the U.S. and globally across different molecular platforms.
"I am excited to join NeoGenomics and be part of a company that is a leader in the oncology space,” Sikri says in the statement. “It is an honor to join the team at this critical time and help launch innovative products like RaDaR that we expect will have a significant impact on cancer patients globally. There is still a lot of work to do to drive the adoption of precision medicine in oncology, especially in the community setting, but with this team and unwavering commitment, I am confident that we will continue to help lead this effort."
Morris was Inivata's top executive for four years, successfully guiding the company through the combination with NeoGenomics in June 2021. During his tenure, he oversaw a number of company successes, including multiple rounds of fundraising, the strategic partnership with and eventual sale to NeoGenomics, and the clinical development and reimbursement process for InVisionFirst-Lung.
"We are pleased to announce the appointment of Vishal Sikri as president and chief commercial officer of Inivata and believe he has the skills needed to lead Inivata to further success. He has extensive experience in the precision oncology space and we will leverage his commercial expertise as we continue to move RaDaR forward with BioPharma and prepare for a launch into the clinical market,” NeoGenomics Executive Chair Lynn Tetrault says in the release.
A publicly traded firm, NeoGenomics specializes in cancer genetics testing and information services, providing comprehensive oncology-focused testing menus in worldwide for physicians to help them diagnose and treat cancer. The company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics has offices in Fort Myers; Tampa; Research Triangle Park, North Carolina; Houston; Atlanta; Nashville, Tennessee; Phoenix; and Aliso Viejo, Carlsbad and San Diego, California. It also has locations in Cambridge, England; Rolle, Switzerland; and Singapore. It posted $483.21 million in revenue.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
